B. Riley Has Negative Forecast for Exagen FY2025 Earnings

Exagen Inc. (NASDAQ:XGN) – Stock analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for Exagen in a note issued to investors on Tuesday, November 4th. B. Riley analyst A. Schock now forecasts that the company will post earnings of ($0.87) per share for the year, down from their prior forecast of ($0.51). B. Riley has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Exagen’s Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.37) EPS.

Other research analysts also recently issued reports about the stock. KeyCorp boosted their price objective on shares of Exagen from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Tuesday, October 14th. BTIG Research boosted their price target on Exagen from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price objective on shares of Exagen in a research note on Wednesday, July 30th. Finally, Canaccord Genuity Group lifted their target price on Exagen from $11.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.83.

Exagen Stock Performance

Shares of Exagen stock opened at $10.38 on Friday. The company has a current ratio of 4.08, a quick ratio of 4.95 and a debt-to-equity ratio of 1.35. The company has a market cap of $235.21 million, a PE ratio of -11.28 and a beta of 1.66. The company has a 50 day moving average of $10.70 and a 200-day moving average of $8.51. Exagen has a 1-year low of $2.43 and a 1-year high of $12.23.

Exagen (NASDAQ:XGN) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $17.24 million for the quarter, compared to analyst estimates of $16.90 million. Exagen had a negative return on equity of 113.48% and a negative net margin of 29.94%. Exagen has set its FY 2025 guidance at EPS.

Institutional Trading of Exagen

Hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Exagen in the first quarter valued at approximately $25,000. XTX Topco Ltd bought a new stake in Exagen during the 2nd quarter worth approximately $133,000. Occudo Quantitative Strategies LP acquired a new position in Exagen in the 2nd quarter valued at approximately $138,000. Bridgeway Capital Management LLC raised its stake in shares of Exagen by 10.3% during the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Exagen during the second quarter worth $217,000. 75.25% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Exagen

In related news, CEO John Aballi sold 31,787 shares of the business’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $11.82, for a total transaction of $375,722.34. Following the sale, the chief executive officer owned 714,427 shares in the company, valued at $8,444,527.14. The trade was a 4.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.60% of the stock is currently owned by company insiders.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).